Filing Flows › Comparisons › RNA vs CNTB
Atrium Therapeutics vs Connect Biopharma Holdings: RNA and CNTB compared
Atrium Therapeutics is the larger company: $3.0M of revenue in its latest quarter (Q2 2026) against $2.8M for Connect Biopharma Holdings (Q2 2026). Connect Biopharma Holdings is growing faster (58× against -22% a year earlier). Connect Biopharma Holdings is more profitable, with an operating margin of -636.0% against -752.9%.
Where the money goes: RNA and CNTB
Atrium Therapeutics (RNA) · Q2 2026
Atrium Therapeutics, Q2 2026: revenue $3.0M (-22% year over year), operating margin -752.9%, net loss $20.2M, operating cash flow −$3.9M. The chart follows the revenue to costs, profit and cash.
Connect Biopharma Holdings (CNTB) · Q2 2026
Connect Biopharma Holdings, Q2 2026: revenue $2.8M (58× year over year), operating margin -636.0%, net loss $17.3M, operating cash flow −$15.9M. The chart follows the revenue to costs, profit and cash.
| Atrium Therapeutics (RNA) | Connect Biopharma Holdings (CNTB) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $3.0M | $2.8M |
| Revenue growth, Y/Y | -22% | 58× |
| Operating margin | -752.9% | -636.0% |
| Net earnings | −$20.2M | −$17.3M |
| Net margin | -672.0% | -624.4% |
| Operating cash flow | −$3.9M | −$15.9M |
Questions
Which is bigger, Atrium Therapeutics or Connect Biopharma Holdings?
Atrium Therapeutics is the larger company: $3.0M of revenue in its latest quarter (Q2 2026) against $2.8M for Connect Biopharma Holdings (Q2 2026).
Is Atrium Therapeutics or Connect Biopharma Holdings growing faster?
Connect Biopharma Holdings is growing faster (58× against -22% a year earlier).
Which is more profitable, Atrium Therapeutics or Connect Biopharma Holdings?
Connect Biopharma Holdings is more profitable, with an operating margin of -636.0% against -752.9%.
More: Atrium Therapeutics earnings · how Atrium Therapeutics makes money · Connect Biopharma Holdings earnings · how Connect Biopharma Holdings makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Aug 12, 2026). Fiscal quarters can end on different dates. Not investment advice.